食管癌和癌前病变组织、食管癌和永生化细胞系中NF-κB和Id-1的变化研究
|
摘要
食管癌 (Esophageal Cancer,EC)是世界上最常见的六大恶性肿瘤之一,具有显著的地域性分布差异,5年生存率仅为10%左右,预后极差。河南省林州市及其毗邻的辉县、安阳等地区是我国,也是世界上食管癌发病率和死亡率最高的地区;过去几十年,国内外科学家对该地区的长期研究提示:食管上皮癌变是一个多阶段演进和多基因变化(累积或叠加)综合作用的结果。食管癌高易感人群早期重要特征是食管基底细胞增生异常,形态学上表现为基底细胞过度增生(basal cell hyperplasia,BCH),间变(dysplasia,DYS)和原位癌(carcinoma in situ,CIS),这些病变被认为是食管癌前病变:食管癌前病变的显著生物学特征是其双向发展的不稳定性,即这些病变可维持多年不变,或向着癌的方向发展,或退回到较轻的病变,那么,决定食管癌前病变不稳定发展的关键因素是什么?特别是形态学相似的癌前病变出现不同方向发展变化的机制是什么?导致轻度癌前病变持续向着癌的方向发展的关键因素是什么?很显然,单纯从形态学的角度难以回答这些问题。我们的假设是:形态学相似的癌前病变可能具有不同的分子变化,这种分子变化可能是导致癌前病变不稳定性发展的关键因素。进一步阐明这种变化的特征和规律,不仅有助于了解食管癌变机制,而且具有重要的临床应用价值(早期诊断,高危人群筛选等)。
我们及其它实验室最近的研究提示:食管癌变演进是多种基因变化先后累积或叠加综合作用的结果。肿瘤抑制基因p53-Rb系统变化是河南食管癌高发区人
Esophageal cancer (EC) is one of the six most common malignant diseases in the world with a remarkable geographical distribution. The prognosis of EC is very poor; five-year survival rate is only about 10 percent for the patients at late or advanced stage. Linzhou city (formerly Linxian) and nearby counties in Henan province have been well-recognized as the high incidence area of EC in the world. In the past decades, studies by the scientists from China and abroad have demonstrated that esophageal carcinogenesis was a multistep progressive process involved by multiple genetic changes (accumulation and overlap). The early characteristic for the subjects predisposed to EC is the abnormal proliferation in epithelial cells, morphologically manifested as basal cell hyperplasia (BCH), dysplasia (DVS) and carcinoma in situ (CIS), which could be considered as precancerous lesions of EC. The precancerous lesions are unstable; it can progress to cancer, or to stay for a couple of years without any changes or even return to normal. What is the most important factor to decide the
precancerous lesions developing to different directions, especially in those precancerous lesions with similar morphological changes? What is the key point to drive the mild precancerous lesions to more severe ones? Our hypothesis is that there may be different molecular changes in the precancerous lesions with similar morphology. To further characterize the molecular changes in esophageal carcinogenesis will shed light on elucidating the mechanisms of EC and establishing the biomarkers for early diagnosis and screening high-risk population.Recent results from our laboratory and others suggest that the esophageal carcinogenesis is a multistep progressive process involved by-multiple genetic changes (accumulation and overlap). High frequencies of p53~Rb changes increasing with lesion progression, suggesting that p53-Rb play a fundamental role in molecular mechanisms of esophageal carcinogenesis. However, many biological events in esophageal carcinogenesis could not be explicated by p53-Rb systems. It is important and necessary to identify some molecules associated with p53-Rb system in esophageal carcinogenesis.The nuclear factor kappa B (NF- κ B) superfamily is one of most important transcription factors, and exists in many types of cells, plays an important role in immune response, transcription, apoptosis, cell-cycle control, cell proliferation, and cell transformation. The NF- κ B family of transcription factors has been shown to be constitutively activated in various human cancer progression and invasion and metastasis. Previous studies demonstrated that NF-κ B is a competitor of p53 during apoptosis thus promoting cell survival. The p53/NF- κ B interaction is not confined to the NF-κB subunit and effects on apoptosis. Instead, by influencing the activity of other family members, p53's effects on the cell cycle can in part be mediated by regulating the activity of distinct NF-κ B subunits.
The inhibitor of differentiation or DNA binding (Id) helix-loop-helix (HLH) proteins are a group of dominant negative regulators of basic HLH transcriptional factors, which promote cell differentiation. Recent evidence has revealed that Id proteins, especially Id-1, are also able to promote cell proliferation and cell cycle progression through inact i vat ion of tumor suppressor genes and activation of growth promoting pathways in mammalian cells. Upregulation of Id-1 has been found in many types of human cancer and its expression levels are also associated with advanced tumor stage. Id—1 transfected human keratinocytes show neither p53-upregulation nor cell cycle arrest after exposure to a DNA damaging agent, actinomycin D, suggesting that Id— 1 impaired p53-mediated DNA damage response. In addition, the increased Id-1 expression in normal cells is associated with both transcriptional and translational suppression of the tumor suppressors pl6I.\K4a, p21WAFl, p27Kipl. Exogenous Id-1 expression in human primary cells delays senescence through inactivation of the pl6INK4a/Rb and p53 tumor suppressor pathways, resulting in life span extension. These results indicate that the ability of Id-1 in promoting normal cell survival may be through interaction with both the p53 and Rb tumor suppressor pathways.The immortalized cell lines are good models to study relative tumors in vitro, which the human papillomavirus (HPV) whole gene or HPV E6^ E7 gene were used to immortal ize any types cells. Subsequent studies using immunologic and molecular methods have confirmed the presence of HPV in EC, and a pathologic role of HPV has been proposed in the development of EC. Two immortalized esophageal epithelial cell models were set up to imitate the malignant transformation process, the human esophageal epithelial cell primary culture, NECA6, was isolated from surgically resected specimens which had been histologically diagnosed as normal esophageal tissue. HPV type 16 (HPV16) E6 and E7 open reading frames, and
hTERT-the catalytic subunit of telomerase-open reading frame were used to infect NECA6. As consequently, two immortalized cell models, NECA6-E6E7 and NECA6-E6E7-hTERT were established. Recent research results by our and others laboratories suggested that there were alteration of some molecules associated with p53-Rb systems in esophageal immortalized cell lines, and these changes were important events in esophageal cell immortalization.There should be a complicated cross-talking between p53-Rb system, NF-k B and Id—1 in cell cycle. It is important and necessary to determine the interaction between p53~Rb system, NF-k B and Id—1 in esophageal carcinogenesis. However, there have been little limited reports on NF- k B^ Id—1 gene changes in esophageal cancer tissue and adjacent tissue with high-risk areas of esophageal cancer. To further elucidate the molecular events involved in the esophageal carcinogenesis, this study was designed to characterize NF-k B^ Id—1 gene expression in EC tissues collected from high-risk area of esophageal cancer and esophageal cancer cells and immortalized cells by immunohistochemical staining, RT-PCR and Western blot, to analyze the effects of pcDNA3/mI k Ba S32A/S36A plasmids, a mutant Ik Ba plasmids of inhibitor of NF-k B, which transfect on the esophageal cancer cell line EC1.1. Materials and Methods1. 1 Surgical and biopsy tissue collection and processingAll the surgically resected primary EC specimens were collected from 65 EC patients in Linzhou, Henan, the high incidence area for EC (35 men and 30 women, 36 to 78 years of age, with a mean +SD of 55 + 7 years). All the patients had not received either chemotherapy or radiotherapy before surgery. Within one hour after excision, the cancer tissue and its adjacent tissue were collected and stored in liquid nitrogen for further
studies.1.2 Pathological diagnosisAll the specimens were confirmed by pathology as esophageal squamous cell carcinoma (SCO, and adjacent tissue confirmed by pathology as basal cell hyperplasia (BCH), dysplasia (DYS) and carcinoma in situ (CIS) according to our laboratories established criterion. 1. 3 Cell linesThe esophageal cancer cell lines EC109, EC1, TE1 were provided by Cancer Research laboratory, Medical College of Zhengzhou University.The esophageal epithelial immortalized cell lines \ECA6-E6E7 and NECA6-E6E7-hTERT were established by the collaboration of Cancer Research Laboratory of Medical College of Zhengzhou University and Microbiology Department in Hong Kong University. Two immortalized esophageal epithelial cell models were set up to imitate the malignant transformation process. NECA6. human esophageal epithelial cell primary culture was isolated from surgically resected specimens which had been his to logically diagnosed as normal. HPV type 16 (HPV16) E6 and E7 open reading frames, and hTERT-the catalytic subunit of telomerase-open reading frame were used to infect NECA6. As result, two immortalization cell models, NECA6-E6E7 and NECA6-E6E7-hTERT were established. 1.4 ImmunohistochemistryThe samples were fixed with 8o'-'o ethanol and embedded with paraffin. Each block was sectioned serially for histopathological analysis and immunohistochemistry analysis. Avidin-biotin complex (ABC) method was used for imrnunohistochemi stry analysis. The criteria and procedure ir, detail for immunostaining was the same as reported in our laboratory previously. All the 65 tissues for SCC and the esophageal cancer cell line and immortalized cell line were applied to determine the \F-k B p65, \F-k B p50 and Id— 1 protein expression with immunohistochemistry
analysis. 1.5 RT-PCRSV Total RNA Isolation System Kit (Promega) was used for RNA extraction, ImProm-IITM Reverse Transcription System Kit (Promega) was used for reverse transcription. The cDNA was prepared for PCR amplification. The 20 cases (38 to 76 years of age, with a mean ±SD of 54±6years, 14 males and 6 females) selected from the total 65 cases were applied to detect NF-k B p65, NF-k B p50 and Id-1 mRNA for RT-PCR study. In addition, 10 biopsy samples collected from the symptom-free subjects (33 to 53 years of age with a mean +SD of 41 + 3 years and 6 males and 4 females) were applied as normal control. The esophageal cancer and immortalized cell lines were also applied to detect NF-k B p65, NF- k B p50 and Id-1 mRNA with RT-PCR. 1. 6 Protein extractions and Western blot analysisM-PER Mammalian Protein Extraction Reagent (Pierce) was used for nuclear extracts. The 20 cases (38 to 76 years of age with a mean +SD of 54 ± 6 years and 14 males and 6 females) selected from the total 65 cases were applied for Western blot analysis. In addition, 10 biopsy samples collected from symptom-free subjects (33 to 53 years of age with a mean + SD of 41 ±3 years and 6 males and 4 females) were applied for Western blot analysis as normal control cases. The tissues nuclear extracts were prepared to detect NF- k B p65, NF- k. B p50 and Id-1 proteins for further Western blot analysis. The esophageal cancer and immortalized cell lines were also applied to detect NF- k B p65, NF-k B p50 and Id-1 protein with Western blot analysis.1.7 The pcDNA3/mIk BaS32A/S36A plasmids transfection in esophageal cancer cell line EC1The pcDNA3/mI k B a S32A/S36A was transfected into EC1 by lipofectimine 2000 method. To observe the growth of esophageal cancer cell
line EC1 was applied to detect inhibitory effect of pCD.\A3/mI k Ba S32A/S36A plasmids in EC1. Western blot analysis and RT-PCR methods were used to detect the NT- k B p65^ NF- k B p50 protein expression and NF-kB p65 and NF-kB p50 mRNA in EC1. 1.8 StatisticsChi-squared test was performed in SPSS (10. 0 version) to evaluate the paired data. The significant difference was considered when the P value was less than 0.05. 2. Results2. 1 Result of NF-k B p65 2. 1. 1 ImmunohistochemistryThe normal esophageal epithelial were negative for NF-kB p65 staining. However, there were 38. 23%, 53.57%, 53. 33% and 69. 23% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and DYS, SCC. P<0. 05 = But there was no significance between the rate of NF-kB p65 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of NF-k B p65 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The NF-k B p65 protein was also expressed in esophageal cancer cell lines EC109, ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.1.2 Western blot analysis on NF-kB p65The nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancer and immortalized cells, and then were analyzed for NF-k B p65 protein expression by western blot. A specific expressed
protein bands at Mr 60XIO1 was found as expected by western blot. The rate of NF- k B p65 protein expression in cancer tissue and adjacent tissue were 50% (10/20) vs. 25% (5/20) . The difference was not significant.The NF-k B p65 protein was observed in the esophageal cancer cell lines EC109> ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2. 1. 3 RT-PCRThe rate of NF- k B p65 mRNA expression in cancer tissues and adjacent tissues were 65%(13/20)vs. 30%(6/20). The difference was not significant, P>0. 05. There was no NF-kB p65 mRNA expression in normal esophageal epithelial tissue.The NF- k. B p65 mRNA were also observed in the esophageal cancer cell lines EC109^ ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.2 NF-k B p50 2. 2. 1 ImmunohistochemistryThe normal esophageal epithelial were negative for NF-k B p50 staining. However, there were 32. 35%, 46.43%, 46. 67% and 61. 54% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and SCC, P<0.05o But there was no significance between the rate of NF- k B p50 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of .NF- k B p50 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The NF-k B p50 protein was also expressed in esophageal cancer cell lines EC109> ECK TE1 and esophageal epithelial immortalized cell lines
NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.2 Western blotThe nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancerous and immortalized cells and analyzed for NF-k B poO protein expression by western blot. A specific expressed protein bands at Mr 50X10' was seen as expected by western blot. The rate of \F- k B p50 protein expression in cancer tissue and adjacent tissue were 45% (9/20) vs. 20% (4/20) , the difference was not significant.The NF-k B p50 protein was also seen in the esophageal cancer cell lines EC109, ECK TE1 and esophageal epithelial immortalized eel 1 lines NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.3 RT-PCRThe rate of NF- k B p50 mRNA expression in cancer tissues and adjacent tissues were 55%( 11/20) vs. 25%(5-/20). The difference was not significant, P>0.05. There was no NF-k B p50 mRNA expression in normal esophageal epithelial tissue.The NF- k B p50 mRNA were also expressed in the esophageal cancer-cell lines EC109, ECK TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.4 Relationship between NF- k B p65 and NF-k B p50In 65 EC samples, the consistent and different expression rates in NF- k B p50 and NF- k B p65 proteins were 49. 23°o (32/65) vs. 50. 77% (33/65), and there were no significant difference, P>0. 05.2. 3 The pcDNA3/mI k Ba S32A/S36A plasmids transfection in the esophageal cancer cell line EC1The esophageal cancer cell line EC1 trans fee led by the pcDNA3/mI k Ba S32A/S36A plasmids was collected and analyzed by western blot. The molecular weight in target protein presented about Mr 65 X 10! and Mr 50X 10! for NF-k B p65 and NF-k B p50.
The two target proteins were detected by western blot in EC1 cells transfected with the pcDNA3. 0 plasmids or without transfection at 0, 24, 48, 96 hours, but not detected the target proteins in the transfected by the pcDNA3/mIk Ba S32A/S36A plasmids.The NF-k B p65 mRNA and NF-k B p50 mRNA were detected by RT-PCR in EC1 cells transfected with by the pcDNA3. 0 plasmids or without, but not detected the target proteins in the transfected by the pcDNA3/mIk B a S32A/S36A plasmids.The tumor cell proliferation analyses demonstrated that the growths of EC1 were inhibited by the pcDNA3/mIk BaS32A/S36A plasmids transfection and without effect in transfected with the pcDNA3. 0 plasmids and without control-transfection by plasmid. Comparisons with EC1 transfected with the pcDNA3. 0 plasmids and without control-transfection, the cell proliferation were significant inhibited in EC1 transfected by the pcDNA3/mIk Ba S32A/S36A plasmids at 0, 24, 48, 96 hours, P<0.05o 2.4 Result of Id-1 2. 4. 1 ImmunohistochemistryThe normal esophageal epithelia were negative for Id—1 staining. However, there were 29. 42%, 46.43%, 60.00% and 63. 07% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and DYS and SCC, P<0.05o There was a significant relationship between the rate of Id-1 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of Id—1 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The Id-1 protein was also expressed in esophageal cancer cell lines
EC109 , EC1 , TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.4. 2 Western blotThe nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancer and immortalized cells and analyzed for Id—1 protein expression by western blot. A specific expressed protein band at Mr 15X10' was seen as expected. The rate of Id— 1 protein expression in cancer tissues and adjacent tissues were 55% (11/20) vs. 20% (4/20) , there were no relationship between cancer tissue and adjacent tissue in rate of Icl-1 protein expression, P>0. 05, the difference was not significant.The Id—1 protein was also seen in the esophageal cancer cell lines EC109, EC1, TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.4.3 RT-PCRThe rate of Id— L mRNA expression in cancer tissues and adjacent tissues were 75% (15/20) vs. 35% (7/20), the difference was not significant. No Icl-1 mRNA expression was observed in normal esophageal epithelial cells. The Id—1 mRNA was expressed in the esophageal cancer cell lines EC109, EC 1. TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 3. Conclusions3. 1 We found that NF- k B p65n NF- k B p50. Id— 1 gene occurred in an early stage for esophageal carcinogenesis, even in BCH. With the lesion progression from mild to severe, the rates of NF-k B p65 and NF- k B p50 expression increased. It indicates that overexpression of NF- k B p65 and NF-k B p50 proteins are frequent molecular events in esophageal precancerous and cancerous lesions, and may play an important role in esophageal carcinogenesis. 3.2 There was a significant relationship between the rate of Id— 1
positive expression and development, and invasion, differentiation and metastasis in EC. It suggests that the alterations of Id—1 gene may be one of the key molecular events in esophageal carcinogenesis.3.3 We detected the proteins and mRNA of NF- k B p65^ NF-k B p50> Id—1 gene in esophageal epithelial immortalized cell lines from high-risk areas of esophageal cancer, and these cell lines could be a good model to further understand the potential molecules associated with p53-Rb system.3.4 We found that the growth of the esophageal cancer cell line EC1 was inhibited by the pcDNA3/mI k. B a S32A/S36A plasmids transfection, a mutant I k B a of NF- k B inhibitor, and the expressions of NF- k B p65^ NF- k. B p50 gene were also inhibited by the pcDNA3/mI k B a S32A/S36A plasmids transfection. The present findings indicate that modulation of NF- k B may be a novel target to design the gene therapy for EC, which is of potential in clinical application.
我们及其它实验室最近的研究提示:食管癌变演进是多种基因变化先后累积或叠加综合作用的结果。肿瘤抑制基因p53-Rb系统变化是河南食管癌高发区人
Esophageal cancer (EC) is one of the six most common malignant diseases in the world with a remarkable geographical distribution. The prognosis of EC is very poor; five-year survival rate is only about 10 percent for the patients at late or advanced stage. Linzhou city (formerly Linxian) and nearby counties in Henan province have been well-recognized as the high incidence area of EC in the world. In the past decades, studies by the scientists from China and abroad have demonstrated that esophageal carcinogenesis was a multistep progressive process involved by multiple genetic changes (accumulation and overlap). The early characteristic for the subjects predisposed to EC is the abnormal proliferation in epithelial cells, morphologically manifested as basal cell hyperplasia (BCH), dysplasia (DVS) and carcinoma in situ (CIS), which could be considered as precancerous lesions of EC. The precancerous lesions are unstable; it can progress to cancer, or to stay for a couple of years without any changes or even return to normal. What is the most important factor to decide the
precancerous lesions developing to different directions, especially in those precancerous lesions with similar morphological changes? What is the key point to drive the mild precancerous lesions to more severe ones? Our hypothesis is that there may be different molecular changes in the precancerous lesions with similar morphology. To further characterize the molecular changes in esophageal carcinogenesis will shed light on elucidating the mechanisms of EC and establishing the biomarkers for early diagnosis and screening high-risk population.Recent results from our laboratory and others suggest that the esophageal carcinogenesis is a multistep progressive process involved by-multiple genetic changes (accumulation and overlap). High frequencies of p53~Rb changes increasing with lesion progression, suggesting that p53-Rb play a fundamental role in molecular mechanisms of esophageal carcinogenesis. However, many biological events in esophageal carcinogenesis could not be explicated by p53-Rb systems. It is important and necessary to identify some molecules associated with p53-Rb system in esophageal carcinogenesis.The nuclear factor kappa B (NF- κ B) superfamily is one of most important transcription factors, and exists in many types of cells, plays an important role in immune response, transcription, apoptosis, cell-cycle control, cell proliferation, and cell transformation. The NF- κ B family of transcription factors has been shown to be constitutively activated in various human cancer progression and invasion and metastasis. Previous studies demonstrated that NF-κ B is a competitor of p53 during apoptosis thus promoting cell survival. The p53/NF- κ B interaction is not confined to the NF-κB subunit and effects on apoptosis. Instead, by influencing the activity of other family members, p53's effects on the cell cycle can in part be mediated by regulating the activity of distinct NF-κ B subunits.
The inhibitor of differentiation or DNA binding (Id) helix-loop-helix (HLH) proteins are a group of dominant negative regulators of basic HLH transcriptional factors, which promote cell differentiation. Recent evidence has revealed that Id proteins, especially Id-1, are also able to promote cell proliferation and cell cycle progression through inact i vat ion of tumor suppressor genes and activation of growth promoting pathways in mammalian cells. Upregulation of Id-1 has been found in many types of human cancer and its expression levels are also associated with advanced tumor stage. Id—1 transfected human keratinocytes show neither p53-upregulation nor cell cycle arrest after exposure to a DNA damaging agent, actinomycin D, suggesting that Id— 1 impaired p53-mediated DNA damage response. In addition, the increased Id-1 expression in normal cells is associated with both transcriptional and translational suppression of the tumor suppressors pl6I.\K4a, p21WAFl, p27Kipl. Exogenous Id-1 expression in human primary cells delays senescence through inactivation of the pl6INK4a/Rb and p53 tumor suppressor pathways, resulting in life span extension. These results indicate that the ability of Id-1 in promoting normal cell survival may be through interaction with both the p53 and Rb tumor suppressor pathways.The immortalized cell lines are good models to study relative tumors in vitro, which the human papillomavirus (HPV) whole gene or HPV E6^ E7 gene were used to immortal ize any types cells. Subsequent studies using immunologic and molecular methods have confirmed the presence of HPV in EC, and a pathologic role of HPV has been proposed in the development of EC. Two immortalized esophageal epithelial cell models were set up to imitate the malignant transformation process, the human esophageal epithelial cell primary culture, NECA6, was isolated from surgically resected specimens which had been histologically diagnosed as normal esophageal tissue. HPV type 16 (HPV16) E6 and E7 open reading frames, and
hTERT-the catalytic subunit of telomerase-open reading frame were used to infect NECA6. As consequently, two immortalized cell models, NECA6-E6E7 and NECA6-E6E7-hTERT were established. Recent research results by our and others laboratories suggested that there were alteration of some molecules associated with p53-Rb systems in esophageal immortalized cell lines, and these changes were important events in esophageal cell immortalization.There should be a complicated cross-talking between p53-Rb system, NF-k B and Id—1 in cell cycle. It is important and necessary to determine the interaction between p53~Rb system, NF-k B and Id—1 in esophageal carcinogenesis. However, there have been little limited reports on NF- k B^ Id—1 gene changes in esophageal cancer tissue and adjacent tissue with high-risk areas of esophageal cancer. To further elucidate the molecular events involved in the esophageal carcinogenesis, this study was designed to characterize NF-k B^ Id—1 gene expression in EC tissues collected from high-risk area of esophageal cancer and esophageal cancer cells and immortalized cells by immunohistochemical staining, RT-PCR and Western blot, to analyze the effects of pcDNA3/mI k Ba S32A/S36A plasmids, a mutant Ik Ba plasmids of inhibitor of NF-k B, which transfect on the esophageal cancer cell line EC1.1. Materials and Methods1. 1 Surgical and biopsy tissue collection and processingAll the surgically resected primary EC specimens were collected from 65 EC patients in Linzhou, Henan, the high incidence area for EC (35 men and 30 women, 36 to 78 years of age, with a mean +SD of 55 + 7 years). All the patients had not received either chemotherapy or radiotherapy before surgery. Within one hour after excision, the cancer tissue and its adjacent tissue were collected and stored in liquid nitrogen for further
studies.1.2 Pathological diagnosisAll the specimens were confirmed by pathology as esophageal squamous cell carcinoma (SCO, and adjacent tissue confirmed by pathology as basal cell hyperplasia (BCH), dysplasia (DYS) and carcinoma in situ (CIS) according to our laboratories established criterion. 1. 3 Cell linesThe esophageal cancer cell lines EC109, EC1, TE1 were provided by Cancer Research laboratory, Medical College of Zhengzhou University.The esophageal epithelial immortalized cell lines \ECA6-E6E7 and NECA6-E6E7-hTERT were established by the collaboration of Cancer Research Laboratory of Medical College of Zhengzhou University and Microbiology Department in Hong Kong University. Two immortalized esophageal epithelial cell models were set up to imitate the malignant transformation process. NECA6. human esophageal epithelial cell primary culture was isolated from surgically resected specimens which had been his to logically diagnosed as normal. HPV type 16 (HPV16) E6 and E7 open reading frames, and hTERT-the catalytic subunit of telomerase-open reading frame were used to infect NECA6. As result, two immortalization cell models, NECA6-E6E7 and NECA6-E6E7-hTERT were established. 1.4 ImmunohistochemistryThe samples were fixed with 8o'-'o ethanol and embedded with paraffin. Each block was sectioned serially for histopathological analysis and immunohistochemistry analysis. Avidin-biotin complex (ABC) method was used for imrnunohistochemi stry analysis. The criteria and procedure ir, detail for immunostaining was the same as reported in our laboratory previously. All the 65 tissues for SCC and the esophageal cancer cell line and immortalized cell line were applied to determine the \F-k B p65, \F-k B p50 and Id— 1 protein expression with immunohistochemistry
analysis. 1.5 RT-PCRSV Total RNA Isolation System Kit (Promega) was used for RNA extraction, ImProm-IITM Reverse Transcription System Kit (Promega) was used for reverse transcription. The cDNA was prepared for PCR amplification. The 20 cases (38 to 76 years of age, with a mean ±SD of 54±6years, 14 males and 6 females) selected from the total 65 cases were applied to detect NF-k B p65, NF-k B p50 and Id-1 mRNA for RT-PCR study. In addition, 10 biopsy samples collected from the symptom-free subjects (33 to 53 years of age with a mean +SD of 41 + 3 years and 6 males and 4 females) were applied as normal control. The esophageal cancer and immortalized cell lines were also applied to detect NF-k B p65, NF- k B p50 and Id-1 mRNA with RT-PCR. 1. 6 Protein extractions and Western blot analysisM-PER Mammalian Protein Extraction Reagent (Pierce) was used for nuclear extracts. The 20 cases (38 to 76 years of age with a mean +SD of 54 ± 6 years and 14 males and 6 females) selected from the total 65 cases were applied for Western blot analysis. In addition, 10 biopsy samples collected from symptom-free subjects (33 to 53 years of age with a mean + SD of 41 ±3 years and 6 males and 4 females) were applied for Western blot analysis as normal control cases. The tissues nuclear extracts were prepared to detect NF- k B p65, NF- k. B p50 and Id-1 proteins for further Western blot analysis. The esophageal cancer and immortalized cell lines were also applied to detect NF- k B p65, NF-k B p50 and Id-1 protein with Western blot analysis.1.7 The pcDNA3/mIk BaS32A/S36A plasmids transfection in esophageal cancer cell line EC1The pcDNA3/mI k B a S32A/S36A was transfected into EC1 by lipofectimine 2000 method. To observe the growth of esophageal cancer cell
line EC1 was applied to detect inhibitory effect of pCD.\A3/mI k Ba S32A/S36A plasmids in EC1. Western blot analysis and RT-PCR methods were used to detect the NT- k B p65^ NF- k B p50 protein expression and NF-kB p65 and NF-kB p50 mRNA in EC1. 1.8 StatisticsChi-squared test was performed in SPSS (10. 0 version) to evaluate the paired data. The significant difference was considered when the P value was less than 0.05. 2. Results2. 1 Result of NF-k B p65 2. 1. 1 ImmunohistochemistryThe normal esophageal epithelial were negative for NF-kB p65 staining. However, there were 38. 23%, 53.57%, 53. 33% and 69. 23% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and DYS, SCC. P<0. 05 = But there was no significance between the rate of NF-kB p65 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of NF-k B p65 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The NF-k B p65 protein was also expressed in esophageal cancer cell lines EC109, ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.1.2 Western blot analysis on NF-kB p65The nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancer and immortalized cells, and then were analyzed for NF-k B p65 protein expression by western blot. A specific expressed
protein bands at Mr 60XIO1 was found as expected by western blot. The rate of NF- k B p65 protein expression in cancer tissue and adjacent tissue were 50% (10/20) vs. 25% (5/20) . The difference was not significant.The NF-k B p65 protein was observed in the esophageal cancer cell lines EC109> ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2. 1. 3 RT-PCRThe rate of NF- k B p65 mRNA expression in cancer tissues and adjacent tissues were 65%(13/20)vs. 30%(6/20). The difference was not significant, P>0. 05. There was no NF-kB p65 mRNA expression in normal esophageal epithelial tissue.The NF- k. B p65 mRNA were also observed in the esophageal cancer cell lines EC109^ ECU TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.2 NF-k B p50 2. 2. 1 ImmunohistochemistryThe normal esophageal epithelial were negative for NF-k B p50 staining. However, there were 32. 35%, 46.43%, 46. 67% and 61. 54% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and SCC, P<0.05o But there was no significance between the rate of NF- k B p50 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of .NF- k B p50 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The NF-k B p50 protein was also expressed in esophageal cancer cell lines EC109> ECK TE1 and esophageal epithelial immortalized cell lines
NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.2 Western blotThe nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancerous and immortalized cells and analyzed for NF-k B poO protein expression by western blot. A specific expressed protein bands at Mr 50X10' was seen as expected by western blot. The rate of \F- k B p50 protein expression in cancer tissue and adjacent tissue were 45% (9/20) vs. 20% (4/20) , the difference was not significant.The NF-k B p50 protein was also seen in the esophageal cancer cell lines EC109, ECK TE1 and esophageal epithelial immortalized eel 1 lines NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.3 RT-PCRThe rate of NF- k B p50 mRNA expression in cancer tissues and adjacent tissues were 55%( 11/20) vs. 25%(5-/20). The difference was not significant, P>0.05. There was no NF-k B p50 mRNA expression in normal esophageal epithelial tissue.The NF- k B p50 mRNA were also expressed in the esophageal cancer-cell lines EC109, ECK TE1 and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT.2.2.4 Relationship between NF- k B p65 and NF-k B p50In 65 EC samples, the consistent and different expression rates in NF- k B p50 and NF- k B p65 proteins were 49. 23°o (32/65) vs. 50. 77% (33/65), and there were no significant difference, P>0. 05.2. 3 The pcDNA3/mI k Ba S32A/S36A plasmids transfection in the esophageal cancer cell line EC1The esophageal cancer cell line EC1 trans fee led by the pcDNA3/mI k Ba S32A/S36A plasmids was collected and analyzed by western blot. The molecular weight in target protein presented about Mr 65 X 10! and Mr 50X 10! for NF-k B p65 and NF-k B p50.
The two target proteins were detected by western blot in EC1 cells transfected with the pcDNA3. 0 plasmids or without transfection at 0, 24, 48, 96 hours, but not detected the target proteins in the transfected by the pcDNA3/mIk Ba S32A/S36A plasmids.The NF-k B p65 mRNA and NF-k B p50 mRNA were detected by RT-PCR in EC1 cells transfected with by the pcDNA3. 0 plasmids or without, but not detected the target proteins in the transfected by the pcDNA3/mIk B a S32A/S36A plasmids.The tumor cell proliferation analyses demonstrated that the growths of EC1 were inhibited by the pcDNA3/mIk BaS32A/S36A plasmids transfection and without effect in transfected with the pcDNA3. 0 plasmids and without control-transfection by plasmid. Comparisons with EC1 transfected with the pcDNA3. 0 plasmids and without control-transfection, the cell proliferation were significant inhibited in EC1 transfected by the pcDNA3/mIk Ba S32A/S36A plasmids at 0, 24, 48, 96 hours, P<0.05o 2.4 Result of Id-1 2. 4. 1 ImmunohistochemistryThe normal esophageal epithelia were negative for Id—1 staining. However, there were 29. 42%, 46.43%, 60.00% and 63. 07% positive staining in the BCH, DYS, CIS and SCC respectively, there were statistically significant comparison to the normal esophageal epithelial(P<0.01). Moreover, the expression was significant between BCH and DYS and SCC, P<0.05o There was a significant relationship between the rate of Id-1 positive expression and invasion, differentiation and metastasis in EC. The heterogeneity of Id—1 proteins expression in EC was observed, which there were strong or weak expression and with or without expression and different distribution in different samples and different cancer nests in the same sample.The Id-1 protein was also expressed in esophageal cancer cell lines
EC109 , EC1 , TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.4. 2 Western blotThe nuclear extracts were collected from cancer and adjacent tissue and the esophageal cancer and immortalized cells and analyzed for Id—1 protein expression by western blot. A specific expressed protein band at Mr 15X10' was seen as expected. The rate of Id— 1 protein expression in cancer tissues and adjacent tissues were 55% (11/20) vs. 20% (4/20) , there were no relationship between cancer tissue and adjacent tissue in rate of Icl-1 protein expression, P>0. 05, the difference was not significant.The Id—1 protein was also seen in the esophageal cancer cell lines EC109, EC1, TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 2.4.3 RT-PCRThe rate of Id— L mRNA expression in cancer tissues and adjacent tissues were 75% (15/20) vs. 35% (7/20), the difference was not significant. No Icl-1 mRNA expression was observed in normal esophageal epithelial cells. The Id—1 mRNA was expressed in the esophageal cancer cell lines EC109, EC 1. TEl and esophageal epithelial immortalized cell lines NECA6-E6E7 and NECA6-E6E7-hTERT. 3. Conclusions3. 1 We found that NF- k B p65n NF- k B p50. Id— 1 gene occurred in an early stage for esophageal carcinogenesis, even in BCH. With the lesion progression from mild to severe, the rates of NF-k B p65 and NF- k B p50 expression increased. It indicates that overexpression of NF- k B p65 and NF-k B p50 proteins are frequent molecular events in esophageal precancerous and cancerous lesions, and may play an important role in esophageal carcinogenesis. 3.2 There was a significant relationship between the rate of Id— 1
positive expression and development, and invasion, differentiation and metastasis in EC. It suggests that the alterations of Id—1 gene may be one of the key molecular events in esophageal carcinogenesis.3.3 We detected the proteins and mRNA of NF- k B p65^ NF-k B p50> Id—1 gene in esophageal epithelial immortalized cell lines from high-risk areas of esophageal cancer, and these cell lines could be a good model to further understand the potential molecules associated with p53-Rb system.3.4 We found that the growth of the esophageal cancer cell line EC1 was inhibited by the pcDNA3/mI k. B a S32A/S36A plasmids transfection, a mutant I k B a of NF- k B inhibitor, and the expressions of NF- k B p65^ NF- k. B p50 gene were also inhibited by the pcDNA3/mI k B a S32A/S36A plasmids transfection. The present findings indicate that modulation of NF- k B may be a novel target to design the gene therapy for EC, which is of potential in clinical application.
引文
1. Correa P. Precursor of gastric and esophageal cancer. Cancer (Phil), 1982; 50 (11 Suppl) :2554
2. Yang CS. Research on esophageal cancer in China: areview. Cancer Res, 1980, 40 (8 Pt 1): 2633
3. Yang CS, Sun Y, Yang QC, Miller KW, Li GY, Zheng SF, Ershow AG, Blot WJ, Li JY. Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Katl Cancer Inst, 1984, 73 (6):1449.
4. Muir CS, McKinney PA. Cancer of the oesophagus: a global overview. Eur J Cancer Prey, 1992, 1 (3):259。
5. Medvec BR. Esophageal cancer: treatment and nursing interventions. Semin Oncol Nuts, 1988, 4(4):246
6. Qiu SL, Yang QR. Precursor lesions of esophageal cancer in high-risk populations in Henan province, China. Cancer, 1988, 62(3):551.
7. Liu FS, Dawsey SM, Wang GQ, Rao M, Lipkin M, Lewin KJ, Li JY, Li B, Taylor PR. Correlation of epithelial proliferation and squamous esophageal histology in 1185 biopsies from Linxian, China. Int J Cancer, 1993, 55(4):577
8. Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol, 2004, 31(4):476.
9. Munro AJ. Oesophageal cancer: a view over overviews. Lancet, 2004, 364(9434):566.
10. Brown A, Shaheen XJ. Screening for upper gastrointestinal tract malignancies. Semin Oncol, 2004, 31(4):487.
11. Wang LD, Qiu SL, Tang GR, Lipkin M, Newmark HL, Tang CS. A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerous lesions in a high-risk population in China. Cancer Epidemiol Biomarkers Prey, 1993, 2(1):71
12. Wang LD, Zhou Q, Gou RY, Xing Y, Zhang BC, Li Qj, Yang CS. Reproducibility of an esophageal biopsy sampling procedure in a high-incidence area for esophageal cancer in northern China. Cancer Epidemiol Biomarkers Prey, 1996, 5(5) :405.
13. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res, 1993, 53(8): 1783
14.王立东,刘宾,郑树。林州居民食管癌p53基因突变谱分析:与其它地区食管和其它类型肿瘤的比较。中华流行病学杂志,2003, 24(3):202.
15. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong. JY, Shao P, qiu SL, Yang CS. Changes in p53 and cyclin Dl protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer, 1994, 59(4):514
16. Wang LD, Zhou Q, Yang WC, Yang CS. Apoptosis and cell proliferation in esophageal precancerous and cancerous lesions: study of a high-risk population in northern China. Anticancer Res, 1999, 19 (1A):369.
17. wang LD, Zhou Q, Yang CS. Esophageal and gastric cardia epithelial cell proliferation in northern Chinese subjects living in a high-incidence area. J Cell Biochem Suppl, 1997, 28-29:159.
18. Wang LD, Zhou Q, Hong.JY, Qiu SL, Yang CS. p53 proteinaccumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Cancer, 1996, 77 (7) :1244.
19. Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, Gao SS, Fan ZM, Zhou Y, Yang CS, Wei JP, Zheng S. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho, 2002, Suppl 1:159.
20. Shi ST, Feng B, Yang GY, Wang LD, Yang CS. Immunohistoselective sequencing (IHSS) of p53 tumor suppressor gene in human oesophageal precancerous lesions. Carcinogenesis, 1996, 17(10):2131-6.
21. Wang ZY, Wang LD, Lee MJ, Ho CT, Huang MT, Conney AN, Yang CS. Inhibition of X-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis, 1995, 16(9):2143.
22. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high- incidence area in north China. World J Gastroenterol, 2003, 9(7):1394.
23. Li J, Feng CW, Zhao ZG, Zhou Q, Wang LD. A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions. World J Gastroenterol, 2000, 6(2):278.
24. Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, Li JL. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol, 2003, 9(1):16.
25. Wang LD, Zheng S, Zheng ZY, Casson AG. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: In special reference to China. World J Gastroenterol, 2003, 9(6):1156.
26.王立东,杨万才,周琦,贾云英。食管癌变过程中p53、c-myc、bcl-2表达及其与细胞凋亡的关系.临床与实验病理学杂志,1998,14(2):106
27.王立东,邹建湘,洪钧言,周琦,Deng Cheng-Jun,Xin Da-Wen,Capasso Holly。食管癌患者O~6-烷基鸟嘌呤-DNA烷基转移酶基因多态性研究.华人消化杂志,1998,6(7):560
28.王立东,周琦,李健,杨万才。食管鳞状细胞癌组织Ras蛋白表达的初步研究.河南医科大学学报,1997,32(1):43
29.王立东,周琦.李健,李永欣,高珊珊。贲门癌原发性病灶和淋巴结转移病灶P53和nm23的变化.河南医科大学学报,1997,32(1):36
30.李健,杨万才,冯常炜,周琦,王立东。食管和贲门癌组织中肿瘤抑制基因maspin的表达.肿瘤防治研究,1999,26(1):1
31.李健,代丽萍,王立东,周琦。1987-1997年间林州市人民医院6502例恶性肿瘤分析。肿瘤防治杂志,2000,7(2):113.
32.王立东,郑树,刘宾,郭瑞锋,王启鸣,范宗民,陈虹,讲理、庄则豪,秦艳茹,安继业,孙超,高社干,李吉林,宋子博,贺新伟,李吉学,李燕杰,高珊珊,郭花芹。河南食管癌高发区居民食管色素镜检查及手术标本碘染色结果分析。郑州大学学报医学版,2002,37(6):729
33.王立东,高珊珊,杜芳,宋子博,范宗民,张延瑞,冯常炜,刘宾。河南食管癌高、低发区无症状人群食管固有膜血管乳头的变化。郑州大学学报医学版,2002,37(6):745
34.安继业,王立东,贺新伟,王启鸣,范宗民,高珊珊,郭花芹。河南食管癌高发区食管癌和贲门癌组织中PTEX蛋白表达变化。郑州大学学报医学版,2002.37 (6):750
35.庄则豪,王立东,王启鸣,秦艳茹,范宗民,高珊珊,陈玉丽,郭花芹。河南食管癌高发区居民食管癌组织中COX-2的表达及其意义。郑州大学学报医学版,2002,37(6):753
36.王立东,郑树。河南食管癌高发区人群食管和贲门癌变机制。郑州大学学报医学版,2002,37(6):717
37.王立东,陈虹。肿瘤抑制基因P53-Rb系统变化与食管癌变关系研究及展望:世界华人消化杂忐,2001,9(4):367
38.秦艳茹,王立东。P53-Rb系统与食管癌。河南医学研究,2001,10(4):371。
39. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995, 24; 80(4):529.
40. Rayet B, Gelinas C. Aberrant rel/NF-kb genes and activity in human cancer. Oncogene. 1999, 18(49): 6938.
41.黄培林。NF-Κ B、IΚ B与肿瘤细胞凋亡。实用癌症杂志。2001,16(1):103
42.向明确。NF-ΚB 抑制物在肿瘤治疗中的研究进展。国外医学肿瘤学分册,2003,30(4):274.
43.牛永东。NF-ΚB 及其在肿瘤中的生物学行为特征。国外医学肿瘤学分册,2002,29(3):168.
44.包倪荣,赵建宁。核因子 kappa B的结构与功能研究进展。医学研究生学报,2003,16(1):59
45.陈庆永。核因子-ΚB 与乳腺癌的研究进展。国外医学外科学分册,2004,31(4):150
46.张劲松,王兴宇。转录因子NF-KB的研究进展。科学通报,2002,47(5):323
47. Lin A, Karin M. NF-kappa B in cancer: a marked target. Semin Cancer Biol, 2003, 13 (2):107.
48. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene, 1999, 18(49):6910.
49. Cyert MS. Regulation of nuclear localization during signaling. J Biol Chem, 2001, 276(24):20805
50. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell, 2004, 6(3):203.
51. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol, 2004, 14 (2):64.
52. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res, 2005, 123(1):158.
53. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med, 2004, 8(4) :445.
54. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through clown regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003, 23(13):4713
55. Webster GA, Perkins ND. Transcript ional cross talk between NF-kappa B and p53. Mol Cell Biol. 1999, 19 (5):3485
56. Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell, 2004, 6(6):539.
57. Norton JD. Id helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci, 2000, 113 (Pt 22):3897.
58. Yokota Y, Mori S. Role of Id family proteins in growth control. J Cell Physiol, 2002, 190(1):21.
59. Wong YC, Wang X, Ling MT. Id-1 expression and cell survival. Apoptosis, 2004, 9(3):279.
60. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of id-1 in prostate cancer. J Urol, 2002, 167(6):2598.
61. Lin CQ, Parrinello S, Campisi J, Desprez PY. Regulation of mammary epithelial cell phenotypes by the helix-loop-helix protein, Id-1. Endocr Relat Cancer, 1999, 6(1):49.
62.冯洁,王永潮。分化抑制因子(Id)家族研究进展。生理科学进展,1997,28(2):139
63.李晓军,秦俊川。细胞分化抑制因子 (Id) 研究进展。生物化学与生物物理进展,2004,31 (10):865
64. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. Id-1 expression promotes cell survival through activation of NF-kappa B signaling pathway in prostate cancer cells. Oncogene, 2003, 22 (29): 4498.
65. Bocchetta M, Carbone M. Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation. Oncogene, 2004, 23(38):6484
66. Stampfer MR, Yaswen P. Human epithelial cell immortalization as a step in carcinogenesis. Cancer Lett, 2003, 194(2):199
67. Lundberg AS, Hahn WC, Gupta P, Weinberg RA. Genes involved in senescence and immortalization. Curr Opin Cell Biol, 2000, 12(6):705
68. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, Garnero A, Beach D. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res, 2005, 65(6): 2179
69. Lawson T, Ouellette M, Kolar C, Hollingsworth M. Culture and immortalization of pancreatic ductal epithelial cells. Methods Mol Med, 2004, 103: 113
70.庄则豪。食管上皮细胞的COX-2表达、调控与细胞永生化及丝裂霉素C抗性。郑州大学2002级博士论文,61
71. Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, Zeng Y. Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell. World J Gastroenterol. 2002, 8(2): 357.
72. Shen ZY, Xu LY, Li EM, Cai WJ, Shen J, Chem MH, ten S, Tsao SW, Zeng Y. The multistage process of carcinogenesis in human esophageal epithelial cells induced by human papillomavirus. Oncol Rep, 2004, 11: 647-54
73. Nakavama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kappa B, I kappa B kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer, 2001, 92(12): 3037
74. Amit S, Ben-Neriah Y. NF-kappa B activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol, 2003, 13(1): 15.
75. Pande V, Ramos MJ. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr Med Chem, 2003, 10(16): 1603.
76. Zhang G, Ghosh S. Molecular mechanisms of NF-kappa B activation induced bv bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res, 2000, 6(6): 453
77. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol, 2001, 38(2): 307.
78. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia, 2001, 15(7): 1011.
79. Kim H, Seo JY, Kim KH. NF-kappa B and cytokines in pancreatic acinar cells, J Korean Med Sci, 2000, 15 Suppl: S53.
80. Shimotobno K. Hepatitis C virus and its pathogenesis. Semin Grocer Biol, 2000, 10(3): 233.
81. Chang AA, Van Waes C. Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma, Adv Otorhinolaryngol, 2005, 62: 92.
82. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB Family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol, 2000, 20(8): 2687.
83. Zurovec M, Petrenko O, Roll R, Enrietto PJ. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation. Oncogene, 1998, 16(24): 3133.
84. Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, Parwaresch RM, Lichter P, Siebert R, Mooller P. Gains of 2p involving the REL locus correlates with nuclear c-Rel protein accumulation in newplastic cells of classical Hodgkin lymphoma. Blood, 2003, 101(9): 3681.
85. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A, 1993, 90(21): 9901.
86. Abdel-Latif MM, O'Riordan J, Windle HJ, Garton E, Ravi N, Kelleher D, Reynolds JV. NF-kappa B activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg, 2004, 239(4): 491.
87. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M. Nuclear factor-kappa B p65(Rel A) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res, 2001, 7(12):4136.
88. Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, Noshiro H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Nuclear factor-kappa B p65 is a prognostic indicator in gastric carcinoma. Anticancer Res, 2004, 24(2C): 1071.
89.陈尧,李瑞祥。人直肠腺癌癌细胞核转录因子κB的表达。华西医科大学学报,2002,33(1):23
90. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B-and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol, 1994, 13; 47(1): 145.
91.高君,赵丽珍。p21ras、核转录因子-κB、cyclinD1在胰腺癌中的表达及其意义。现代肿瘤医学,2003,11(4):245。
92. Ling W, Rayman P, Uzzo R, Clark P, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T, Finke J. Impaired activation of NF kappa B in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, I kappa B alpha. Blood, 1998, 92(4): 1334.
93.谢东华,唐孝达,夏术阶。核转录因子NF-κB在膀胱癌中的表达及临床意义。癌症,2002,21(6):663.
94. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281(5383): 1680.
95. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol, 1999, 19(4): 2690.
96. Frank V, Adi G. Neoplasia. In: Cotran RS, Kumar V and Robbins SL. Robbins Pathologic Basis of Disease, 5th edition. Philadelphia: W B Saunders Co, 1994: 257.
97. Ling MT, Wang X, Ouyang XS, Lee TK, Fan TY, Xu K, Tsao SW, Wong YC. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene, 2002, 21(55): 8498.
98.王云川。Id-1基因与前列腺癌之关系。解剖与临床,2002,7(4):131
99. Singh J, Murata K, Itahana Y, Desprez PY. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene, 2002, 21(12): 1812.
100. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, Korc M. Id-1 and Id-2 are overexpressed in pamereatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol, 1999, 155(3): 815.
101. Langlands K, Down GA, Kealey T. Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell careinoma. Cancer Res, 2000, 60(21): 5929.
102. Nishimine M, Nakamura M, Mishima K, Kishi M, Kirita T, Sugimura M, Konishi N. Id proteins are overexpressed in human oral squamous cell careinomas. J Oral Pathol Med, 2003, 32(6): 350.
103.庞栋,沈宏,范天勇。膀胱移行细胞癌Id-1表达的实验研究。现代泌尿外科学杂志,2004,9(3):134
104. Wang X, Xu K, Ling MT, Wong YC, Feng HC, Nicholls J, Tsao SW. Evidence of increased Id-1 expression and its role in cell proliferation in nasopharyngeal carcinoma cells. Mol Carcinog, 2002, 35(1): 42.
105. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis, 2002, 23(5): 721.
106. Alani RM, Hasskarl 1, Grace M, Hernandez MC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci U S A, 1999, 96(17): 9637.
107. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther, 2002, 1(13): 1181.
108. Si HX, Tsao SW, Poon CS, Wane LD, Wong YC, Cheung AL. Viral load of HPV in esophageal squamous cell carcinoma. Int J Cancer, 2003, 103(4): 496
2. Yang CS. Research on esophageal cancer in China: areview. Cancer Res, 1980, 40 (8 Pt 1): 2633
3. Yang CS, Sun Y, Yang QC, Miller KW, Li GY, Zheng SF, Ershow AG, Blot WJ, Li JY. Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Katl Cancer Inst, 1984, 73 (6):1449.
4. Muir CS, McKinney PA. Cancer of the oesophagus: a global overview. Eur J Cancer Prey, 1992, 1 (3):259。
5. Medvec BR. Esophageal cancer: treatment and nursing interventions. Semin Oncol Nuts, 1988, 4(4):246
6. Qiu SL, Yang QR. Precursor lesions of esophageal cancer in high-risk populations in Henan province, China. Cancer, 1988, 62(3):551.
7. Liu FS, Dawsey SM, Wang GQ, Rao M, Lipkin M, Lewin KJ, Li JY, Li B, Taylor PR. Correlation of epithelial proliferation and squamous esophageal histology in 1185 biopsies from Linxian, China. Int J Cancer, 1993, 55(4):577
8. Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol, 2004, 31(4):476.
9. Munro AJ. Oesophageal cancer: a view over overviews. Lancet, 2004, 364(9434):566.
10. Brown A, Shaheen XJ. Screening for upper gastrointestinal tract malignancies. Semin Oncol, 2004, 31(4):487.
11. Wang LD, Qiu SL, Tang GR, Lipkin M, Newmark HL, Tang CS. A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerous lesions in a high-risk population in China. Cancer Epidemiol Biomarkers Prey, 1993, 2(1):71
12. Wang LD, Zhou Q, Gou RY, Xing Y, Zhang BC, Li Qj, Yang CS. Reproducibility of an esophageal biopsy sampling procedure in a high-incidence area for esophageal cancer in northern China. Cancer Epidemiol Biomarkers Prey, 1996, 5(5) :405.
13. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res, 1993, 53(8): 1783
14.王立东,刘宾,郑树。林州居民食管癌p53基因突变谱分析:与其它地区食管和其它类型肿瘤的比较。中华流行病学杂志,2003, 24(3):202.
15. Wang LD, Shi ST, Zhou Q, Goldstein S, Hong. JY, Shao P, qiu SL, Yang CS. Changes in p53 and cyclin Dl protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer, 1994, 59(4):514
16. Wang LD, Zhou Q, Yang WC, Yang CS. Apoptosis and cell proliferation in esophageal precancerous and cancerous lesions: study of a high-risk population in northern China. Anticancer Res, 1999, 19 (1A):369.
17. wang LD, Zhou Q, Yang CS. Esophageal and gastric cardia epithelial cell proliferation in northern Chinese subjects living in a high-incidence area. J Cell Biochem Suppl, 1997, 28-29:159.
18. Wang LD, Zhou Q, Hong.JY, Qiu SL, Yang CS. p53 proteinaccumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. Cancer, 1996, 77 (7) :1244.
19. Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, Gao SS, Fan ZM, Zhou Y, Yang CS, Wei JP, Zheng S. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. Gan To Kagaku Ryoho, 2002, Suppl 1:159.
20. Shi ST, Feng B, Yang GY, Wang LD, Yang CS. Immunohistoselective sequencing (IHSS) of p53 tumor suppressor gene in human oesophageal precancerous lesions. Carcinogenesis, 1996, 17(10):2131-6.
21. Wang ZY, Wang LD, Lee MJ, Ho CT, Huang MT, Conney AN, Yang CS. Inhibition of X-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by green and black tea. Carcinogenesis, 1995, 16(9):2143.
22. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high- incidence area in north China. World J Gastroenterol, 2003, 9(7):1394.
23. Li J, Feng CW, Zhao ZG, Zhou Q, Wang LD. A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions. World J Gastroenterol, 2000, 6(2):278.
24. Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, Li JL. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. World J Gastroenterol, 2003, 9(1):16.
25. Wang LD, Zheng S, Zheng ZY, Casson AG. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: In special reference to China. World J Gastroenterol, 2003, 9(6):1156.
26.王立东,杨万才,周琦,贾云英。食管癌变过程中p53、c-myc、bcl-2表达及其与细胞凋亡的关系.临床与实验病理学杂志,1998,14(2):106
27.王立东,邹建湘,洪钧言,周琦,Deng Cheng-Jun,Xin Da-Wen,Capasso Holly。食管癌患者O~6-烷基鸟嘌呤-DNA烷基转移酶基因多态性研究.华人消化杂志,1998,6(7):560
28.王立东,周琦,李健,杨万才。食管鳞状细胞癌组织Ras蛋白表达的初步研究.河南医科大学学报,1997,32(1):43
29.王立东,周琦.李健,李永欣,高珊珊。贲门癌原发性病灶和淋巴结转移病灶P53和nm23的变化.河南医科大学学报,1997,32(1):36
30.李健,杨万才,冯常炜,周琦,王立东。食管和贲门癌组织中肿瘤抑制基因maspin的表达.肿瘤防治研究,1999,26(1):1
31.李健,代丽萍,王立东,周琦。1987-1997年间林州市人民医院6502例恶性肿瘤分析。肿瘤防治杂志,2000,7(2):113.
32.王立东,郑树,刘宾,郭瑞锋,王启鸣,范宗民,陈虹,讲理、庄则豪,秦艳茹,安继业,孙超,高社干,李吉林,宋子博,贺新伟,李吉学,李燕杰,高珊珊,郭花芹。河南食管癌高发区居民食管色素镜检查及手术标本碘染色结果分析。郑州大学学报医学版,2002,37(6):729
33.王立东,高珊珊,杜芳,宋子博,范宗民,张延瑞,冯常炜,刘宾。河南食管癌高、低发区无症状人群食管固有膜血管乳头的变化。郑州大学学报医学版,2002,37(6):745
34.安继业,王立东,贺新伟,王启鸣,范宗民,高珊珊,郭花芹。河南食管癌高发区食管癌和贲门癌组织中PTEX蛋白表达变化。郑州大学学报医学版,2002.37 (6):750
35.庄则豪,王立东,王启鸣,秦艳茹,范宗民,高珊珊,陈玉丽,郭花芹。河南食管癌高发区居民食管癌组织中COX-2的表达及其意义。郑州大学学报医学版,2002,37(6):753
36.王立东,郑树。河南食管癌高发区人群食管和贲门癌变机制。郑州大学学报医学版,2002,37(6):717
37.王立东,陈虹。肿瘤抑制基因P53-Rb系统变化与食管癌变关系研究及展望:世界华人消化杂忐,2001,9(4):367
38.秦艳茹,王立东。P53-Rb系统与食管癌。河南医学研究,2001,10(4):371。
39. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995, 24; 80(4):529.
40. Rayet B, Gelinas C. Aberrant rel/NF-kb genes and activity in human cancer. Oncogene. 1999, 18(49): 6938.
41.黄培林。NF-Κ B、IΚ B与肿瘤细胞凋亡。实用癌症杂志。2001,16(1):103
42.向明确。NF-ΚB 抑制物在肿瘤治疗中的研究进展。国外医学肿瘤学分册,2003,30(4):274.
43.牛永东。NF-ΚB 及其在肿瘤中的生物学行为特征。国外医学肿瘤学分册,2002,29(3):168.
44.包倪荣,赵建宁。核因子 kappa B的结构与功能研究进展。医学研究生学报,2003,16(1):59
45.陈庆永。核因子-ΚB 与乳腺癌的研究进展。国外医学外科学分册,2004,31(4):150
46.张劲松,王兴宇。转录因子NF-KB的研究进展。科学通报,2002,47(5):323
47. Lin A, Karin M. NF-kappa B in cancer: a marked target. Semin Cancer Biol, 2003, 13 (2):107.
48. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene, 1999, 18(49):6910.
49. Cyert MS. Regulation of nuclear localization during signaling. J Biol Chem, 2001, 276(24):20805
50. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell, 2004, 6(3):203.
51. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol, 2004, 14 (2):64.
52. Wu JT, Kral JG. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res, 2005, 123(1):158.
53. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med, 2004, 8(4) :445.
54. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through clown regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003, 23(13):4713
55. Webster GA, Perkins ND. Transcript ional cross talk between NF-kappa B and p53. Mol Cell Biol. 1999, 19 (5):3485
56. Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell, 2004, 6(6):539.
57. Norton JD. Id helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci, 2000, 113 (Pt 22):3897.
58. Yokota Y, Mori S. Role of Id family proteins in growth control. J Cell Physiol, 2002, 190(1):21.
59. Wong YC, Wang X, Ling MT. Id-1 expression and cell survival. Apoptosis, 2004, 9(3):279.
60. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of id-1 in prostate cancer. J Urol, 2002, 167(6):2598.
61. Lin CQ, Parrinello S, Campisi J, Desprez PY. Regulation of mammary epithelial cell phenotypes by the helix-loop-helix protein, Id-1. Endocr Relat Cancer, 1999, 6(1):49.
62.冯洁,王永潮。分化抑制因子(Id)家族研究进展。生理科学进展,1997,28(2):139
63.李晓军,秦俊川。细胞分化抑制因子 (Id) 研究进展。生物化学与生物物理进展,2004,31 (10):865
64. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. Id-1 expression promotes cell survival through activation of NF-kappa B signaling pathway in prostate cancer cells. Oncogene, 2003, 22 (29): 4498.
65. Bocchetta M, Carbone M. Epidemiology and molecular pathology at crossroads to establish causation: molecular mechanisms of malignant transformation. Oncogene, 2004, 23(38):6484
66. Stampfer MR, Yaswen P. Human epithelial cell immortalization as a step in carcinogenesis. Cancer Lett, 2003, 194(2):199
67. Lundberg AS, Hahn WC, Gupta P, Weinberg RA. Genes involved in senescence and immortalization. Curr Opin Cell Biol, 2000, 12(6):705
68. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, Garnero A, Beach D. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res, 2005, 65(6): 2179
69. Lawson T, Ouellette M, Kolar C, Hollingsworth M. Culture and immortalization of pancreatic ductal epithelial cells. Methods Mol Med, 2004, 103: 113
70.庄则豪。食管上皮细胞的COX-2表达、调控与细胞永生化及丝裂霉素C抗性。郑州大学2002级博士论文,61
71. Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, Zeng Y. Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell. World J Gastroenterol. 2002, 8(2): 357.
72. Shen ZY, Xu LY, Li EM, Cai WJ, Shen J, Chem MH, ten S, Tsao SW, Zeng Y. The multistage process of carcinogenesis in human esophageal epithelial cells induced by human papillomavirus. Oncol Rep, 2004, 11: 647-54
73. Nakavama H, Ikebe T, Beppu M, Shirasuna K. High expression levels of nuclear factor kappa B, I kappa B kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer, 2001, 92(12): 3037
74. Amit S, Ben-Neriah Y. NF-kappa B activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol, 2003, 13(1): 15.
75. Pande V, Ramos MJ. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr Med Chem, 2003, 10(16): 1603.
76. Zhang G, Ghosh S. Molecular mechanisms of NF-kappa B activation induced bv bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res, 2000, 6(6): 453
77. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol, 2001, 38(2): 307.
78. White MK, McCubrey JA. Suppression of apoptosis: role in cell growth and neoplasia. Leukemia, 2001, 15(7): 1011.
79. Kim H, Seo JY, Kim KH. NF-kappa B and cytokines in pancreatic acinar cells, J Korean Med Sci, 2000, 15 Suppl: S53.
80. Shimotobno K. Hepatitis C virus and its pathogenesis. Semin Grocer Biol, 2000, 10(3): 233.
81. Chang AA, Van Waes C. Nuclear factor-KappaB as a common target and activator of oncogenes in head and neck squamous cell carcinoma, Adv Otorhinolaryngol, 2005, 62: 92.
82. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB Family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol, 2000, 20(8): 2687.
83. Zurovec M, Petrenko O, Roll R, Enrietto PJ. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation. Oncogene, 1998, 16(24): 3133.
84. Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, Parwaresch RM, Lichter P, Siebert R, Mooller P. Gains of 2p involving the REL locus correlates with nuclear c-Rel protein accumulation in newplastic cells of classical Hodgkin lymphoma. Blood, 2003, 101(9): 3681.
85. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A, 1993, 90(21): 9901.
86. Abdel-Latif MM, O'Riordan J, Windle HJ, Garton E, Ravi N, Kelleher D, Reynolds JV. NF-kappa B activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg, 2004, 239(4): 491.
87. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M. Nuclear factor-kappa B p65(Rel A) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res, 2001, 7(12):4136.
88. Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, Noshiro H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Nuclear factor-kappa B p65 is a prognostic indicator in gastric carcinoma. Anticancer Res, 2004, 24(2C): 1071.
89.陈尧,李瑞祥。人直肠腺癌癌细胞核转录因子κB的表达。华西医科大学学报,2002,33(1):23
90. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B-and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol, 1994, 13; 47(1): 145.
91.高君,赵丽珍。p21ras、核转录因子-κB、cyclinD1在胰腺癌中的表达及其意义。现代肿瘤医学,2003,11(4):245。
92. Ling W, Rayman P, Uzzo R, Clark P, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T, Finke J. Impaired activation of NF kappa B in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, I kappa B alpha. Blood, 1998, 92(4): 1334.
93.谢东华,唐孝达,夏术阶。核转录因子NF-κB在膀胱癌中的表达及临床意义。癌症,2002,21(6):663.
94. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281(5383): 1680.
95. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol, 1999, 19(4): 2690.
96. Frank V, Adi G. Neoplasia. In: Cotran RS, Kumar V and Robbins SL. Robbins Pathologic Basis of Disease, 5th edition. Philadelphia: W B Saunders Co, 1994: 257.
97. Ling MT, Wang X, Ouyang XS, Lee TK, Fan TY, Xu K, Tsao SW, Wong YC. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene, 2002, 21(55): 8498.
98.王云川。Id-1基因与前列腺癌之关系。解剖与临床,2002,7(4):131
99. Singh J, Murata K, Itahana Y, Desprez PY. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene, 2002, 21(12): 1812.
100. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, Korc M. Id-1 and Id-2 are overexpressed in pamereatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol, 1999, 155(3): 815.
101. Langlands K, Down GA, Kealey T. Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell careinoma. Cancer Res, 2000, 60(21): 5929.
102. Nishimine M, Nakamura M, Mishima K, Kishi M, Kirita T, Sugimura M, Konishi N. Id proteins are overexpressed in human oral squamous cell careinomas. J Oral Pathol Med, 2003, 32(6): 350.
103.庞栋,沈宏,范天勇。膀胱移行细胞癌Id-1表达的实验研究。现代泌尿外科学杂志,2004,9(3):134
104. Wang X, Xu K, Ling MT, Wong YC, Feng HC, Nicholls J, Tsao SW. Evidence of increased Id-1 expression and its role in cell proliferation in nasopharyngeal carcinoma cells. Mol Carcinog, 2002, 35(1): 42.
105. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis, 2002, 23(5): 721.
106. Alani RM, Hasskarl 1, Grace M, Hernandez MC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci U S A, 1999, 96(17): 9637.
107. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther, 2002, 1(13): 1181.
108. Si HX, Tsao SW, Poon CS, Wane LD, Wong YC, Cheung AL. Viral load of HPV in esophageal squamous cell carcinoma. Int J Cancer, 2003, 103(4): 496